Clinical Trial Update: FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating FLX475 in combination with pembrolizumab for advanced or metastatic gastric cancer has completed, with results posted on 2025-09-25.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• FLX475 (FLX475)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-09-25